Suven Life Sciences gets Product Patents in Brazil and Eurasia
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
New Delhi: Suven Life Sciences Thursday said it has been granted a product patent by Brazil and Eurasia each for a new chemical entity (NCE) used in the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023 and 2034, respectively, the company said in a BSE filing.
The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added.
Read Also: Suven Life Sciences gets Product Patents in Australia and Hong Kong
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
Read Also: Suven Life Sciences gets Product Patents in Israel and Japan
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd